The group’s principle activity is to develop therapeutic and diagnostic agents for Alzheimer’s disease and other related neurodegenerative diseases that are associated with tau protein. The group operates from United States.
Executive Information
Name
Title
Email
Stephen Eisold
Dir., CEO
N/A
Sam Khatami
Co - Founder, Dir., VP - Operations
N/A
Ferid Murad
Dir., Investor, Member - Scientific Advisory Board
